Taysha reports FY2024 net loss $89.3M; TSHA-102 well tolerated in all 10 patients across REVEAL trials

Taysha Gene Therapies, Inc.

2024-FY EPS reported -$0.36 revenue$8,333,000

Net loss $89.3M ($0.36/sh) vs $111.6M ($0.96/sh) in FY2023; cash $139.0M, runway into Q4 2026.
TSHA-102 (Rett syndrome) no treatment-related SAEs or DLTs in all 10 patients (6 high dose, 4 low dose) as of Feb 17, 2025 cutoff.
Dosing of Part A in both REVEAL Phase 1/2 trials completed; pivotal trial design update expected H1 2025.
R&D expenses $66.0M (up $9.2M YoY) driven by GMP manufacturing and clinical activities; G&A $29.0M (down $1.0M).
Safety and efficacy data from high-dose cohorts (n=3 each) and low-dose updates expected H1 2025 for both adolescent/adult and pediatric trials.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.